, /PRNewswire/ -- , a clinical-stage biotech company, has appointed as chief medical officer. This strategic move follows Dr. Galloway's recent addition to the company's scientific advisory board and marks a significant step in CureLab's innovative approach to addressing a broad spectrum of inflammation-related diseases.
Dr. Galloway, a renowned cardiac surgeon and the Seymour Cohn Professor of Cardiothoracic Surgery at NYU Langone Health, brings extensive expertise in clinical trials, cardiovascular disease research, and an understanding of host inflammatory mediators of a variety of inflammatory diseases to this new position at CureLab Oncology. Dr.
Galloway will continue his full-time appointment at NYU Langone, but his background in biomedical research, medical device development, and clinical trials will bring significant synergy to CureLab's scientific team. "While oncology will always be our primary focus, the discoveries we make will naturally lead us to a broader field of chronic inflammatory diseases," said , CEO of CureLab Oncology. "Dr.
Galloway's understanding of host inflammatory mechanisms and the role that plays in various diseases, and his history of collaboration with experts in inflammation-related fields, make him the ideal candidate to guide the development of our next-generation therapies." In his new role, Dr. Galloway will oversee the clinical development strategy for CureLab's lead investigational compound, ElenagenTM, as well as new forms of treatmen.
